Search
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14386ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Synonyms: Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated)Lodoxamide
go.drugbank.com/drugs/DB06794ApprovedLodoxamide is marketed under the brand name Alomide by Alcon.
Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamateProducts: THILOMIDE GÖZ DAMLASI, 5 ML, ALOMİDE % 0.1 GÖZ DAMLASI, ÇÖZELTİ, 5 MLIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14602ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Synonyms: Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (UV, formaldehyde inactivated)Naftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
Products: DERMIFIN %1 SPREY, 20 ML, FUNDERYL %1 SPREY, 20 MLReserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnThe FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942] … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Synonyms: (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl esterMixtures: Hydropres 50 Tab, REGROTON TABLET, 50 ADETVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigational[A253702] Furthermore, vonoprazan is 350-times more potent than the proton-pump inhibitor [lansoprazole], thanks to its ability to accumulate in the gastric corpus mucosa, specifically in the parietal … Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations.
Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalRelapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. … This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure.
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalRadiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology. … Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.
Mixtures: Micro+ Te PediatricProducts: Sodium Iodide Inj 100mg/ml, TAEK-PHT 123I-NAI (SODYUM İYODÜR) 37 MBQ/ML I.V. ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETPegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase
Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML